We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.30 billion. The consensus mark for earnings is pinned at $1.51 per share.
Let us see how things might have shaped up for Zoetis in the soon-to-be-reported quarter.
Factors to Consider Regarding ZTS’ Q3 Earnings
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments, the United States and International.
Third-quarter revenues in the U.S. segment are likely to have decreased from the year-ago quarter, primarily due to lower sales of Zoetis’ companion animal products and an increasingly competitive landscape, partially offset by the growth in the parasiticides portfolio, including Simparica and ProHeart franchises, and its key dermatology products, including Apoquel and Cytopoint. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.17 billion.
Revenues from the International segment are expected to have increased in the to-be-reported quarter due to higher sales of its companion animal and livestock products. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.11 billion.
Year to date, Zoetis shares have plunged 32.4% compared with the industry’s 2.3% decline.
Image Source: Zacks Investment Research
However, Zoetis’ monoclonal antibody products for osteoarthritis pain, Librela for dogs and Solensia for cats, are likely to have remained under pressure in the U.S. market.Softer end-market demand and increased price sensitivity are expected to have weighed on sales for these products.
Apoquel is also approved as the first and only chewable treatment in the United States for controlling pruritus related to allergic dermatitis and treating atopic dermatitis in dogs at least 12 months of age. The drug’s expanded label is likely to continue contributing to Zoetis' dermatology revenues.
In 2025, the FDA approved a new indication for Zoetis’ Simparica Trio to prevent flea tapeworm infections by targeting and killing vector fleas in treated dogs. With this approval, the triple-combination drug is now the only canine combination parasiticide indicated to prevent flea tapeworm infections at the source by eliminating carrier fleas before they can transmit the parasite. The expanded indication, along with demand for its broad-spectrum parasite protection, could have supported Simparica Trio sales in the to-be-reported quarter.
Zoetis' livestock product sales are expected to have increased in the third quarter, supported by continued broad-based strength across its core species portfolio. In the United States, growth is likely to have been driven by cattle, poultry and swine products, while the International segment is expected to have benefited from broad-based demand across cattle, swine, poultry and fish.
The recent FDA approval of Convenia RTU for dogs is a positive pipeline-to-commercialization development for Zoetis, expanding its companion animal dermatology portfolio. The single-dose injectable formulation offers greater convenience than traditional oral antibiotics and could support veterinarian adoption. However, the product is unlikely to contribute significantly to the soon-to-be-reported quarter's revenues, with its financial benefits expected to emerge gradually as commercialization progresses.
ZTS Earnings Surprise History
Zoetis has a mixed earnings surprise history so far. The bottom line surpassed estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 1.83%. In the last reported quarter, the company delivered a surprise of 1.63%.
Earnings Whispers for ZTS
Our proven model does not predict an earnings beat for Zoetis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: ZTS has an Earnings ESP of +2.16%, as the Most Accurate Estimate currently stands at earnings of $1.54, higher than the Zacks Consensus Estimate, which is pegged at earnings of $1.51.
Zacks Rank: Zoetis currently carries a Zacks Rank #4 (Sell).
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present.
Shares of TGTX have surged 101.1% year to date. The company’s earnings missed estimates in three of the trailing four quarters and beat in the remaining one, delivering the average surprise of 184.65%.
Jasper Therapeutics (JSPR - Free Report) has an Earnings ESP of +66.67% and a Zacks Rank #2 at present.
Shares of JSPR have gained 72.3% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering the average surprise of 25.04%.
Iovance Biotherapeutics (IOVA - Free Report) has an Earnings ESP of +44.44% and a Zacks Rank #2 at present.
Shares of IOVA have skyrocketed 193.8% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering the average surprise of 16.82%. Iovance Biotherapeutics is scheduled to reportits third-quarter results on Nov. 5.
View the Zacks #1 Rank List
Image: Bigstock
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
Key Takeaways
Zoetis, Inc. (ZTS - Free Report) is slated to report third-quarter results on Nov. 5, 2026, before the opening bell.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.30 billion. The consensus mark for earnings is pinned at $1.51 per share.
Let us see how things might have shaped up for Zoetis in the soon-to-be-reported quarter.
Factors to Consider Regarding ZTS’ Q3 Earnings
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments, the United States and International.
Third-quarter revenues in the U.S. segment are likely to have decreased from the year-ago quarter, primarily due to lower sales of Zoetis’ companion animal products and an increasingly competitive landscape, partially offset by the growth in the parasiticides portfolio, including Simparica and ProHeart franchises, and its key dermatology products, including Apoquel and Cytopoint. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.17 billion.
Revenues from the International segment are expected to have increased in the to-be-reported quarter due to higher sales of its companion animal and livestock products. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.11 billion.
Year to date, Zoetis shares have plunged 32.4% compared with the industry’s 2.3% decline.
Image Source: Zacks Investment Research
However, Zoetis’ monoclonal antibody products for osteoarthritis pain, Librela for dogs and Solensia for cats, are likely to have remained under pressure in the U.S. market.Softer end-market demand and increased price sensitivity are expected to have weighed on sales for these products.
Apoquel is also approved as the first and only chewable treatment in the United States for controlling pruritus related to allergic dermatitis and treating atopic dermatitis in dogs at least 12 months of age. The drug’s expanded label is likely to continue contributing to Zoetis' dermatology revenues.
In 2025, the FDA approved a new indication for Zoetis’ Simparica Trio to prevent flea tapeworm infections by targeting and killing vector fleas in treated dogs. With this approval, the triple-combination drug is now the only canine combination parasiticide indicated to prevent flea tapeworm infections at the source by eliminating carrier fleas before they can transmit the parasite. The expanded indication, along with demand for its broad-spectrum parasite protection, could have supported Simparica Trio sales in the to-be-reported quarter.
Zoetis' livestock product sales are expected to have increased in the third quarter, supported by continued broad-based strength across its core species portfolio. In the United States, growth is likely to have been driven by cattle, poultry and swine products, while the International segment is expected to have benefited from broad-based demand across cattle, swine, poultry and fish.
The recent FDA approval of Convenia RTU for dogs is a positive pipeline-to-commercialization development for Zoetis, expanding its companion animal dermatology portfolio. The single-dose injectable formulation offers greater convenience than traditional oral antibiotics and could support veterinarian adoption. However, the product is unlikely to contribute significantly to the soon-to-be-reported quarter's revenues, with its financial benefits expected to emerge gradually as commercialization progresses.
ZTS Earnings Surprise History
Zoetis has a mixed earnings surprise history so far. The bottom line surpassed estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 1.83%. In the last reported quarter, the company delivered a surprise of 1.63%.
Earnings Whispers for ZTS
Our proven model does not predict an earnings beat for Zoetis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: ZTS has an Earnings ESP of +2.16%, as the Most Accurate Estimate currently stands at earnings of $1.54, higher than the Zacks Consensus Estimate, which is pegged at earnings of $1.51.
Zacks Rank: Zoetis currently carries a Zacks Rank #4 (Sell).
Zoetis Inc. Price and Consensus
Zoetis Inc. price-consensus-chart | Zoetis Inc. Quote
Stocks to Consider
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present.
Shares of TGTX have surged 101.1% year to date. The company’s earnings missed estimates in three of the trailing four quarters and beat in the remaining one, delivering the average surprise of 184.65%.
Jasper Therapeutics (JSPR - Free Report) has an Earnings ESP of +66.67% and a Zacks Rank #2 at present.
Shares of JSPR have gained 72.3% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering the average surprise of 25.04%.
Iovance Biotherapeutics (IOVA - Free Report) has an Earnings ESP of +44.44% and a Zacks Rank #2 at present.
Shares of IOVA have skyrocketed 193.8% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering the average surprise of 16.82%. Iovance Biotherapeutics is scheduled to reportits third-quarter results on Nov. 5.